Methylphenidate and the risk of psychotic disorders and hallucinations in children and adolescents in a large health system

K. K. C. Man, D. Coghill, E. W. Chan, W. C. Y. Lau, C. Hollis, E. Liddle, T. Banaschewski, S. McCarthy, A. Neubert, K. Sayal, P. Ip, I. C. K. Wong (Lead / Corresponding author)

    Research output: Contribution to journalArticle

    16 Citations (Scopus)
    137 Downloads (Pure)

    Abstract

    Previous studies have suggested that risk of psychotic events may be increased in children exposed to methylphenidate (MPH). However, this risk has not been fully examined, and the possibility of confounding factors has not been excluded. Patients aged 6-19 years who received at least one MPH prescription were identified using Hong Kong population-based electronic medical records on the Clinical Data Analysis and Reporting System (2001-2014). Using the self-controlled case series design, relative incidence of psychotic events was calculated comparing periods when patients were exposed to MPH with non-exposed periods. Of 20,586 patients prescribed MPH, 103 had an incident psychotic event; 72 (69.9%) were male and 31 (30.1%) female. The mean age at commencement of observation was 6.95 years and the mean follow-up per participant was 10.16 years. On average, each participant was exposed to MPH for 2.17 years. The overall incidence of psychotic events during the MPH exposure period was 6.14 per 10,000 patient-years. No increased risk was found during MPH-exposed compared with non-exposed periods (incidence rate ratio (IRR) 1.02 (0.53-1.97)). However, an increased risk was found during the pre-exposure period (IRR 4.64 (2.17-9.92)). Results were consistent across all sensitivity analyses. This study does not support the hypothesis that MPH increases risk of incident psychotic events. It does indicate an increased risk of psychotic events before the first prescription of MPH, which may be because of an association between psychotic events and the behavioural and attentional symptoms that led to psychiatric assessment and initiation of MPH treatment.

    Original languageEnglish
    Article numbere956
    Pages (from-to)1-7
    Number of pages7
    JournalTranslational Psychiatry
    Volume6
    Issue number11
    DOIs
    Publication statusPublished - 15 Nov 2016

    Keywords

    • ADHD
    • Schizophrenia

    Fingerprint Dive into the research topics of 'Methylphenidate and the risk of psychotic disorders and hallucinations in children and adolescents in a large health system'. Together they form a unique fingerprint.

  • Cite this

    Man, K. K. C., Coghill, D., Chan, E. W., Lau, W. C. Y., Hollis, C., Liddle, E., Banaschewski, T., McCarthy, S., Neubert, A., Sayal, K., Ip, P., & Wong, I. C. K. (2016). Methylphenidate and the risk of psychotic disorders and hallucinations in children and adolescents in a large health system. Translational Psychiatry, 6(11), 1-7. [e956]. https://doi.org/10.1038/tp.2016.216